Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia

nano-technology — Formation of nanoparticles for the oral delivery of small molecules by Flash Nanoprecipitation

The present study aimed to develop nanolipid carrier (NLC) loaded transdermal system of rivastigmine for bioavailability enhancement. NLC was optimized using Box-Behnken Design (BBD). Optimized formulation comprises oil (4% w/w), tween 80 (3% w/w) and span 80 (1.8% w/w) and was characterized.

Enhanced mechanical and antimicrobial properties of hydroxypropyl methylcellulose films incorporating silver nanoparticles for wound dressing applications

Formulation development, in-vitro and ex-vivo evaluation of dry adsorbed solid lipid nanoparticles: an approach of overcoming olanzapine drawbacks

Shin-Etsu AQOAT® – Enteric coating polymer and solid dispersion carrier

It was found that the formulation exhibit 134.60 ± 15.10 nm, 0.286 ± 0.041, -11.80 ± 2.24 mV and 70.56 ± 1.20 % of mean size, polydispersity index (PDI), zeta potential and entrapment efficiency, respectively. In vitro release studies showed there was more sustained release of drug from NLC loaded transdermal patches in comparison to Exelon® patch. Skin irritation studies proved the non-irritant nature of developed NLC based transdermal patch.

From pharmacokinetic studies it was observed that there was increased Cmax and AUC0-72 in plasma treated with NLC loaded transdermal patches as compared to conventional patch. These experimental results indicate that NLC based transdermal patch could be utilized as a potential carrier for enhancing bioavailability of rivastigmine for the better treatment and management of dementia. More on nanolipid carrier

excipients lipid